IRIS
MACCARONI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.669
EU - Europa 798
AS - Asia 241
AF - Africa 46
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.756
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.669
IT - Italia 222
UA - Ucraina 154
SE - Svezia 101
IE - Irlanda 94
CN - Cina 76
DE - Germania 76
DK - Danimarca 61
TR - Turchia 60
SG - Singapore 57
KR - Corea 32
CI - Costa d'Avorio 31
FI - Finlandia 31
GB - Regno Unito 24
FR - Francia 16
MA - Marocco 12
BE - Belgio 11
IN - India 10
DZ - Algeria 3
NL - Olanda 3
AT - Austria 2
EU - Europa 2
JP - Giappone 2
PH - Filippine 2
VN - Vietnam 2
CZ - Repubblica Ceca 1
HR - Croazia 1
RO - Romania 1
Totale 2.756
Salva come PNG Salva come JPEG
Città #
Chandler 256
Jacksonville 169
Fairfield 164
Ashburn 109
Dublin 94
Boardman 88
Wilmington 84
Ann Arbor 79
Woodbridge 74
New York 72
Centro 69
Houston 63
Seattle 58
Cambridge 55
Des Moines 38
Lawrence 36
Princeton 36
San Mateo 35
Abidjan 31
Turin 27
Singapore 20
Beijing 18
Ancona 17
San Diego 15
Brussels 10
Pune 9
Los Angeles 7
Washington 7
Cagliari 6
Dallas 5
Falconara Marittima 5
Helsinki 5
London 5
Marche 5
Wuxi 5
Jiaxing 4
New Bedfont 4
Shanghai 4
Wuhan 4
Amsterdam 3
Florence 3
Guangzhou 3
Kilburn 3
Milan 3
Shenzhen 3
Bari 2
Clifton 2
Dong Ket 2
Hanover 2
Izmir 2
Kagoya 2
Modena 2
Palermo 2
Porto 2
Roseto degli Abruzzi 2
Sassari 2
Savona 2
Scafati 2
Serradifalco 2
Vienna 2
Acerra 1
Acton 1
Ascoli Piceno 1
Chiswick 1
Civitanova Marche 1
Falkenstein 1
Foligno 1
Frankfurt (Oder) 1
Hangzhou 1
Hounslow 1
Jinhua 1
Naples 1
New Delhi 1
Norwalk 1
Olomouc 1
Pesaro 1
Phoenix 1
Prescot 1
Quzhou 1
Rome 1
San Benedetto Del Tronto 1
San Francisco 1
Santa Clara 1
Seoul 1
Sioux Falls 1
Southwark 1
Suzhou 1
Torre Del Greco 1
Waterloo 1
Yiwu 1
Zibo 1
Totale 1.871
Salva come PNG Salva come JPEG
Nome #
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 131
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 117
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 105
Optimal management of resected gastric cancer 101
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 96
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 92
Adjuvant treatment after surgical resection 88
Caratterizzazione istologica e molecolare nelle pazienti con carcinoma ovarico sporadico ed ereditario 87
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 87
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. 85
5-Fluorouracil pharmacogenomics: still rocking after all these years? 83
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 83
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. 82
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 81
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 81
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 80
Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer 80
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 79
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 79
Transient sunitinib resistance in gastrointestinal stromal tumors. 78
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 75
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 75
Locally advanced rectal cancer: the importance of a multidisciplinary approach. 70
Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. 70
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 69
Developments in the management of advanced soft-tissue sarcoma –€“ Olaratumab in context 66
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 65
Locally advanced rectal cancer: new findings in anticancer therapy 64
Expectations and psychological issues before genetic counseling: analysis of distress determinant factors 64
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 61
Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. 60
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 58
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy 55
The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language? 54
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type 50
Thymic epithelial tumors (TETs) and additional tumors: a single Centre experience 50
State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. 34
Totale 2.835
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.369
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.369
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020193 0 0 0 6 33 0 35 7 33 7 15 57
2020/2021624 32 66 110 11 75 32 33 52 45 82 49 37
2021/2022309 25 77 9 5 1 15 16 22 14 41 19 65
2022/2023697 51 93 50 54 51 101 1 45 146 6 84 15
2023/2024380 57 8 26 45 51 105 4 13 1 8 7 55
2024/2025172 102 56 14 0 0 0 0 0 0 0 0 0
Totale 2.835